Patents Assigned to IRM LLC
  • 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
    Patent number: 7893074
    Abstract: Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: February 22, 2011
    Assignees: Novartis AG, IRM LLC
    Inventors: Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
  • Antagonists of protease activated receptor-1 (PAR1)
    Patent number: 7888483
    Abstract: The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: February 15, 2011
    Assignee: IRM LLC
    Inventors: Steve B Cohen, Marc Nasoff
  • COMPOSITIONS AND METHODS FOR TREATING CANCERS
    Publication number: 20110021524
    Abstract: This invention provides a combination of ATP-competitive BCR-ABL inhibitor and a non-ATP competitive BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with BCR-ABL.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 27, 2011
    Applicant: IRM LLC
    Inventors: Francisco Adrian, Christine Dierks, Nathanael S. Gray, Markus Warmuth
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7868018
    Abstract: The invention provides compounds of Formula I: wherein R1-R6 are described in the Summary of the Invention; the pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK2?2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR?, PKA, PKB?, PKD2, Rsk1, SAPK2?, SAPK2?, SAPK3, SGK, Tie2 and TrkB kinases.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: January 11, 2011
    Assignee: IRM LLC
    Inventors: Yongping Xie, Guobao Zhang, Xing Wang, Nathanael S. Gray, Yi Liu
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20110003798
    Abstract: The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT*, c-Kit, RET, TrkA, TrkB, TrkC-GR-1R, Alk, c-FMS or combinations thereof.
    Type: Application
    Filed: January 27, 2009
    Publication date: January 6, 2011
    Applicant: IRM LLC
    Inventors: Barun Okram, Tetsuo Uno, Qiang Ding, Yahua Liu, Yunho Jin, Qihui Jin, Xu Wu, Jianwei Che, S. Frank Yan, Xueshi Hao
  • PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110003790
    Abstract: The invention provides a class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Syk, ZAP70, KDR, FMS, FLT3, c-Kit, RET, TrkA, TrkB, TrkC, IGR-IR, AIk, c-FMS, or combinations thereof.
    Type: Application
    Filed: January 27, 2009
    Publication date: January 6, 2011
    Applicant: IRM LLC
    Inventors: Qiang Ding, Yahua Liu, Xu Wu, Qihui Jin, Jianwei Che, S. Frank Yan
  • ANTAGONIST ANTIBODIES OF PROTEASE ACTIVATED RECEPTOR-1 (PAR1)
    Publication number: 20100330090
    Abstract: The present invention provide antibodies or antigen-binding molecules that specifically recognize and antagonize the PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: July 17, 2008
    Publication date: December 30, 2010
    Applicant: IRM LLC
    Inventor: Kenneth R. Luehrsen
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20100324062
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Aurora-A, Axl, BMX, CHK2, c-RAF, cSRC, Fes, FGFR3, Flt3, IKK?, IR, JNK2?2, Lck, Met, MKK6, MST2, p70S6K, PDGFR?, PKA, PKD2, ROCK-II, Ros, Rsk1, SAPK2?, SAPK2?, SAPK3, SAPK4, Syk, Tie2 and TrkB kinases.
    Type: Application
    Filed: October 20, 2006
    Publication date: December 23, 2010
    Applicant: IRM LLC
    Inventors: Advait Nagle, Nathanael S. Gray
  • Compounds and compositions as protein kinase inhbitors
    Patent number: 7846923
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFR?, Ros, SAPK2?, SGK, SIK, Syk, Tie2 and TrkB kinases.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: December 7, 2010
    Assignee: IRM LLC
    Inventors: Pingda Ren, Baogen Wu, Guobao Zhang, Yongping Xie, Barun Okram, Victor Nikulin, Xia Wang, Ha-Soon Choi
  • Compounds and compositions as LXR modulators
    Patent number: 7846949
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: December 7, 2010
    Assignee: IRM LLC
    Inventors: Valentina Molteni, Xiaolin Li, Fang Liang, Juliet Nabakka, Enrique Saez, John Wityak
  • 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20100298295
    Abstract: The invention provides novel pyrimidine derivatives of formula (1) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).
    Type: Application
    Filed: August 27, 2008
    Publication date: November 25, 2010
    Applicant: IRM LLC
    Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Badry Bursulaya, Christian Cho-Hua Lee, Nathanael S. Gray
  • Compounds and compositions as PPAR modulators
    Patent number: 7820705
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: October 26, 2010
    Assignee: IRM LLC
    Inventors: Robert Epple, Ross Russo, Mihai Azimioara, Yongping Xie
  • Compounds and compositions as TPO mimetics
    Patent number: 7816542
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: October 19, 2010
    Assignee: IRM LLC
    Inventors: Thomas Marsilje, Wenshuo Lu, Phillip B. Alper, Daniel Mutnick, Yun He
  • Spiro-containing compounds and compositions as modulators of steroid hormone nuclear receptors
    Patent number: 7807841
    Abstract: Described herein are compounds that have a spiro structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent diseases or conditions associated with the activity of steroid hormone nuclear receptors.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: October 5, 2010
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Chi Ching Mak, Wei Pei
  • COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
    Publication number: 20100239551
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating chan-nel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSSI1E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Application
    Filed: January 4, 2008
    Publication date: September 23, 2010
    Applicant: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Agnes Vidal, Badry Bursulaya
  • COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS
    Publication number: 20100234400
    Abstract: The present invention relates to methods and compositions for culturing embryonic stem (ES) cells. The methods relate to growing the ES cells in the presence of small molecules of formula (I) that maintain the pluripotency/self-renewal of the cells without feeder cells and LIF in serum-free conditions. These methods in part facilitate much more consistency in embryonic stem cell production, providing, for example, new avenues in the practical applications of embryonic stem cells in regenerative medicine.
    Type: Application
    Filed: June 8, 2006
    Publication date: September 16, 2010
    Applicants: IRM LLC, The Scripps Research Institute
    Inventors: Shuibing Chen, Sheng Ding, Feng Yan, Peter G. Schultz
  • COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
    Publication number: 20100234406
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
    Type: Application
    Filed: May 2, 2008
    Publication date: September 16, 2010
    Applicants: IRM LLC, Novartis AG
    Inventors: Xiaolin Li, Xiaodong Liu, Valentina Molteni, Donatella Chianelli, Jon Loren, Juliet Nabakka, Timothy Ramsey, Werner Breitenstein
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY
    Publication number: 20100234365
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
    Type: Application
    Filed: December 12, 2007
    Publication date: September 16, 2010
    Applicant: IRM LLC
    Inventors: Hong Liu, Xiaohui He, Dean Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
  • INHIBITORS OF CATHEPSIN S
    Publication number: 20100204200
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: wherein Q is an optionally substituted azetidinyl, pyrrolidinyl, piperidyl, and indolinyl; or Q is NR25R26; and A, R5, R6, R7, R8, R9, R25, R26 and Ar are substituents.
    Type: Application
    Filed: April 21, 2010
    Publication date: August 12, 2010
    Applicant: IRM LLC
    Inventors: Hong Liu, Arnab Chatterjee, David C. Tully, Phillip Alper, Badry Bursulaya, Jianhua Guo, David H. Woodmansee, Daniel Mutnick, Donald S. Karanewsky, Yun He
  • BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS
    Publication number: 20100197659
    Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    Type: Application
    Filed: June 4, 2008
    Publication date: August 5, 2010
    Applicant: IRM LLC
    Inventors: Christine Dierks, Markus Warmuth, Xu Wu